Overexpression of Smac promotes cisplatin-induced apoptosis by activating caspase-3 and caspase-9 in lung cancer A549 cells

Cancer Biotherapy and Radiopharmaceuticals

Volumn 28, Issue 2, 2013, Pages 177-182

  Qin, Sida ^a   Yang, Chengcheng ^a   Wang, Xifang ^a   Xu, Chongwen ^a   Li, Shuo ^a   Zhang, Boxiang ^a   Ren, Hong ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

apoptosis; caspase; cisplatin; lung cancer; Smac

Indexed keywords

BENZYLOXYCARBONYLLEUCYLGLUTAMYLHISTIDYLASPARTYL FLUOROMETHYL KETONE; CASPASE 3; CASPASE 9; CISPLATIN; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL ASSAY; CELL COUNT; CELL GROWTH; CELL VIABILITY; CONTROLLED STUDY; CYTOSOL; FLOW CYTOMETRY; GROWTH CURVE; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MITOCHONDRION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STABLE TRANSFECTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CASPASE 8; CASPASE 9; CELL PROLIFERATION; CISPLATIN; CYTOSOL; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MITOCHONDRIA; MITOCHONDRIAL PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 84874674178     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2012.1261     Document Type: Article

References (36)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69.
2. Siegel R, Naishadham D, Jemal A. Cancer Statistics, 2012. CA Cancer J Clin 2012;62:10.
3. Depierre A, Milleron B, Moro-Sibilot D, et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa nonsmall- cell lung cancer. J Clin Oncol 2002;20:247.
4. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. New Engl J Med 2002;346:92.
5. D'Addario G, Pintilie M, Leighl NB, et al. Platinum-based versus non-platinum-based chemotherapy in advanced nonsmall- cell lung cancer: A meta-analysis of the published literature. J Clin Oncol 2005;23:2926.
6. De Marinis F, Migliorino MR, Paoluzzi L, et al. Phase I/II trial of gemcitabine plus cisplatin and etoposide in patients with small-cell lung cancer. Lung Cancer 2003;39:331.
7. Herbst RS, Heymach JV, Lippman SM. Molecular origins of cancer: Lung cancer. New Engl J Med 2008;359:1367.
8. Du CY, Fang M, Li YC, et al. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000;102:33.
9. Verhagen AM, Ekert PG, Pakusch M, et al. a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000;102:43.
10. Munoz-Pinedo C, Guio-Carrion A, Goldstein JC, et al. Different mitochondrial-intermembrane space proteins are released during apoptosis in a manner that is coordinately initiated but can vary in duration. Proc Natl Acad Sci U S A 2006;103:11573.
11. Huang Y, Park YC, Rich RL, et al. Structural basis of caspase inhibition by XIAP: Differential roles of the linker versus the BIR domain. Cell 2001;104:781.
12. Fandy TE, Shankar S, Srivastava RK. Smac/DIABLO enhances the therapeutic potential of chemotherapeutic drugs and irradiation, and sensitizes TRAIL-resistant breast cancer cells. Mol Cancer 2008;7:60.
13. McNeish IA, Bell S, McKay T, et al. Expression of Smac/ DIABLO in ovarian carcinoma cells induces apoptosis via a caspase-9-mediated pathway. Exp Cell Res 2003;286:186.
14. McNeish IA, Lopes R, Bell SJ, et al. Survivin interacts with Smac/DIABLO in ovarian carcinoma cells but is redundant in Smac-mediated apoptosis. Exp Cell Res 2005;302:69.
15. Sekimura A, Konishi A, Mizuno K, et al. Expression of Smac/DIABLO is a novel prognostic marker in lung cancer. Oncol Rep 2004;11:797.
16. Dai CH, Li J, Shi SB, et al. Survivin and Smac gene expressions but not livin are predictors of prognosis in nonsmall cell lung cancer patients treated with adjuvant chemotherapy following surgery. Jpn J Clin Oncol 2010; 40:327.
17. Chen P, Li J, Ge LP, et al. Prognostic value of survivin, X-linked inhibitor of apoptosis protein and second mitochondriaderived activator of caspases expression in advanced nonsmall- cell lung cancer patients. Respirology 2010;15:501.
18. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351.
19. Rajeswaran A, Trojan A, Burnand B, et al. Efficacy and side effects of cisplatin-and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: A systematic review of randomized controlled trials. Lung Cancer 2008;59:1.
20. Yang X, Fraser M, Moll UM, et al. Akt-mediated cisplatin resistance in ovarian cancer: Modulation of p53 action on caspase-dependent mitochondrial death pathway. Cancer Res 2006;66:3126.
21. Ferreira CG, Span SW, Peters GJ, et al. Chemotherapy triggers apoptosis in a caspase-8-dependent and mitochondriacontrolled manner in the non-small cell lung cancer cell line NCI-H460. Cancer Res 2000;60:7133.
22. Zeng H, Zhang S, Yang KY, et al. Knockdown of second mitochondria-derived activator of caspase expression by RNAi enhances growth and cisplatin resistance of human lung cancer cells. Cancer Biother Radiopharm 2010;25:705.
23. Yang YL, Li XM. The IAP family: Endogenous caspase inhibitors with multiple biological activities. Cell Res 2000;10:169.
24. Shiozaki EN, Shi Y. Caspases, IAPs and Smac/DIABLO: Mechanisms from structural biology. Trends Biochem Sci 2004;29:486.
25. Deveraux QL, Reed JC. IAP family proteins - suppressors of apoptosis. Genes Dev 1999;13:239.
26. Sun C, Cai M, Meadows RP, et al. NMR structure and mutagenesis of the third Bir domain of the inhibitor of apoptosis protein XIAP. J Biol Chem 2000;275:33777.
27. Wu G, Chai J, Suber TL, et al. Structural basis of IAP recognition by Smac/DIABLO. Nature 2000;408:1008.
28. Srinivasula SM, Hegde R, Saleh A, et al. A conserved XIAPinteraction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. Nature 2001;410:112.
29. Liu Z, Sun C, Olejniczak ET, et al. Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain. Nature 2000;408:1004.
30. Qin S, Yang C, Li S, et al. Smac: Its role in apoptosis induction and use in lung cancer diagnosis and treatment. Cancer Lett 2012;318:9.
31. Yang Xu, Lanping Zhou, Jing Huang, et al. Role of Smac in determining the chemotherapeutic response of esophageal squamous cell carcinoma. Clin Cancer Res 2011;17:5412.
32. Petersen SL, Wang L, Yalcin-Chin A, et al. Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell 2007;12:445.
33. Bai L, Chen W, Wang X, et al. Attenuating Smac mimetic compound 3-induced NF-kB activation by luteolin leads to synergistic cytotoxicity in cancer cells. J Cell Biochem 2009;108:1125.
34. Petersen SL, Peyton M, Minna JD, et al. Overcoming cancer cell resistance to Smac mimetic induced apoptosis by modulating cIAP-2 expression. Proc Natl Acad Sci U S A 2010;107:11936.
35. Li L, Thomas RM, Suzuki H, et al. A small molecule Smac mimic potentiates TRAIL-and TNF alpha-mediated cell death. Science 2004;305:1471.
36. Hossbach J, Michalsky E, Henklein P, et al. Inhibiting the inhibitors: Retro-inverso Smac peptides. Peptides 2009; 30:2374.